The COVID-19 pandemic catalysed the adoption of Decentralised Clinical Trials (DCTs) even though they have been in use for decades. DCTs offer the advantage of enabling patients to take part in clinical studies from the convenience of their homes, eliminating the need for them to travel to clinical sites. This not only reduces the burden on patients but also leads to higher participation rates. Against this backdrop, out of the virtual components used in clinical trials, mobile healthcare is the most commonly used component, with 47 per cent of DCTs using this element, reveals GlobalData
GlobalData’s latest report “Thematic Intelligence: Digital Transformation and Emerging Technologies in the Healthcare Industry,” reveals that web-based technology is the second most commonly used virtual component, with 23 per cent of DCTs using it for activities such as electronic data collection (eCOA, eConsent, eDiary, ePRO, and questionnaire).
Mobile healthcare consists of activities such as remote patient monitoring, remote drug delivery, telemedicine, and home nursing.